Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging

Radiology

Volumn 218, Issue 2, 2001, Pages 365-374

  Padhani, A R ^a   MacVicar, A D ^a   Gapinski, C J ^a   Dearnaley, D P ^a   Parker, G J M ^a   Suckling, J ^a   Leach, M O ^a   Husband, J E ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Hormones; Magnetic resonance (MR), contrast enhancement; Prostate neoplasms; Prostate neoplasms, MR; Prostate neoplasms, therapy

Indexed keywords

GONADORELIN DERIVATIVE;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER DIAGNOSIS; CANCER STAGING; CAPILLARY PERMEABILITY; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; IMAGE INTENSIFIER; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; SEMINAL VESICLE; TECHNIQUE; TUMOR VOLUME;

EID: 0035145865     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.218.2.r01ja04365     Document Type: Article

References (73)

1. Results of conservative management of clinically localized prostate cancer
2. Surgical treatment of carcinoma of the prostate
3. The role of radiation therapy in stages A2 and B adenocarcinoma of the prostate
4. The role of neoadjuvant hormonal manipulation in localized prostatic cancer
5. Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer
6. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate
7. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer
8. Phase III Radiation Oncology Group (RTOG) 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate
9. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group
10. A phase III randomised trial to evaluate the efficacy of neoadjuvant therapy prior to curative radiotherapy in locally advanced prostate cancer patients: A Canadian Urologic Oncology Group study
11. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy proceeded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer: The Lupron Depot Neoadjuvant Prostate Cancer Study Group
12. Neoadjuvant hormonal therapy: The Canadian experience
13. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer: Canadian Urologic Oncology Group
14. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
15. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma: The European Study Group on Neoadjuvant Treatment of Prostate Cancer
16. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy
17. Androgen deprivation and radiation therapy: Sequencing studies using the Shionogi in vivo tumor system
18. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation
19. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate
20. Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide
21. Hormonal ablation of prostatic cancer: Effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging
22. Effects of endocrine therapy on the primary lesion in patients with prostate carcinoma as evaluated by endorectal magnetic resonance imaging
23. Dynamic contrast enhanced MRI in human tumors
24. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
25. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats
26. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor
27. Histologic grading of prostate cancer: A perspective
28. Normal pelvic lymph nodes: Evaluation with CT after bipedal lymphangiography
29. MR imaging abbreviations, definitions, and descriptions: A review
30. Probing tumor microvessel density by measurement, analysis and display of contrast agent uptake kinetics
31. Improving image quality and T(1) measurements using saturation recovery turboFLASH with an approximate K-space normalisation filter
32. Prostate carcinoma: Assessment of diagnostic criteria for capsular penetration on endorectal coil MR images
33. MRIW: Parametric analysis software for contrast-enhanced dynamic MR imaging in cancer
34. Dynamic breast MR imaging: Are signal intensity time course data useful for differential diagnosis of enhancing lesions?
35. Studies of Gd-DTPA relaxivity and proton exchange rates in tissue
36. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. I. Fundamental concepts
37. Quantitative analysis of Dynamic Gd-DTPA enhancement in breast tumors using a permeability model
38. Estimated kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: Standardized quantities and symbols
39. Kinetic evaluation of the effect of LHRH analogue on prostatic cancer using transrectal ultrasonotomography
40. Transrectal ultrasonography in the evaluation of patients with prostatic carcinoma
41. Radiotherapy of prostate cancer: Established results and new developments
42. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: Effects on the volume of normal tissue irradiation
43. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia
44. MR imaging of the seminal vesicles
45. Pathologic changes associated with androgen deprivation therapy for prostate cancer
46. Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect): Distinction from poor tumor differentiation
47. Squamous metaplasia of the prostate following estrogen therapy
48. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique
49. Staging urinary bladder cancer after transurethral biopsy: Value of fast dynamic contrast-enhanced MR imaging
50. Benign and malignant musculoskeletal lesions: Dynamic contrast-enhanced MR imaging parametric "first-pass" images depict tissue vascularization and perfusion
51. Dynamic turboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: Correlation with histopathologic results
52. Differentiation of prostatic carcinoma and benign prostatic hyperplasia: Correlation between dynamic Gd-DTPA-enhanced MR imaging and histopathology
53. Dynamic contrast enhanced MRI of prostate cancer: Correlation with morphology and tumour stage, histological grade and PSA
54. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy
55. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: A new noninvasive predictive assay
56. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging
57. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: Value of dynamic MR imaging in detecting viable tumor before surgery
58. Kinetic study of tumor blood flow in prostatic cancer using power Doppler imaging
59. Dynamic contrast-enhanced subtraction versus T2-weighted spin-echo MR imaging in the follow-up of colorectal neoplasm: A prospective study of 41 patients
60. Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: Preliminary results in 26 patients
61. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia
62. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells
63. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
64. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation
65. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP
66. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element
67. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP
68. Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status?
69. Local staging of prostate carcinoma with endorectal coil MRl: Correlation with whole-mount radical prostatectomy specimens
70. Staging of prostate cancer: Results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques
71. Staging of prostatic cancer: Accuracy of MR imaging
72. Magnetic resonance imaging of prostate cancer: Comparison of image quality using endorectal and pelvic phased array coils